Equillium Inc (EQ) Actualités

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD...

Equillium to Present at the Stifel Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel...

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Dual and synergistic signaling of IL-15 and IL-21 robustly augments NK and CD8 T cell responses Highlights importance of dual inhibition or...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Combination of IL-15 and IL-21 robustly augments NK and CD8 T cell activity Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company...